Karl Swedberg

100.8k total citations · 31 hit papers
507 papers, 64.0k citations indexed

About

Karl Swedberg is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Karl Swedberg has authored 507 papers receiving a total of 64.0k indexed citations (citations by other indexed papers that have themselves been cited), including 446 papers in Cardiology and Cardiovascular Medicine, 94 papers in Pulmonary and Respiratory Medicine and 53 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Karl Swedberg's work include Heart Failure Treatment and Management (365 papers), Cardiovascular Function and Risk Factors (152 papers) and Cardiac pacing and defibrillation studies (109 papers). Karl Swedberg is often cited by papers focused on Heart Failure Treatment and Management (365 papers), Cardiovascular Function and Risk Factors (152 papers) and Cardiac pacing and defibrillation studies (109 papers). Karl Swedberg collaborates with scholars based in Sweden, United States and United Kingdom. Karl Swedberg's co-authors include John J.V. McMurray, John Kjekshus, Marc A. Pfeffer, Salim Yusuf, Eric L. Michelson, Christopher B. Granger, Scott D. Solomon, Jan Östergren, Bertil Olofsson and Michel Komajda and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Karl Swedberg

494 papers receiving 61.4k citations

Hit Papers

Angiotensin–Neprilysin In... 1981 2026 1996 2011 2014 1988 2010 2003 2003 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
    2014 4.3k citations John J.V. McMurray, Milton Packer et al. profile →
  2. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
    1988 3.0k citations Karl Swedberg et al. profile →
  3. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
    2010 2.0k citations Faı̈ez Zannad, John J.V. McMurray et al. profile →
  4. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    2003 2.0k citations Salim Yusuf, Marc A. Pfeffer et al. profile →
  5. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    2003 1.8k citations John J.V. McMurray, Jan Östergren et al. profile →
  6. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    2010 1.7k citations Karl Swedberg, Michel Komajda et al. profile →
  7. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
    2003 1.7k citations Marc A. Pfeffer, John J.V. McMurray et al. profile →
  8. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
    2005 1.7k citations Karl Swedberg, John G.F. Cleland et al. profile →
  9. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    2003 1.3k citations Marc A. Pfeffer, Karl Swedberg et al. profile →
  10. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    2003 1.3k citations Karl Swedberg, John G.F. Cleland et al. profile →
  11. Person-Centered Care — Ready for Prime Time
    2011 1.2k citations Inger Ekman, Karl Swedberg et al. profile →
  12. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    2003 1.1k citations Christopher B. Granger, John J.V. McMurray et al. profile →
  13. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
    2004 955 citations John J.V. McMurray, Milton Packer et al. Circulation profile →
  14. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.
    1990 906 citations Karl Swedberg et al. Circulation profile →
  15. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
    1993 902 citations Karl Swedberg et al. profile →
  16. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
    2012 846 citations Stuart Pocock, John J.V. McMurray et al. profile →
  17. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
    2010 822 citations Michael Böhm, Karl Swedberg et al. profile →
  18. CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL
    2003 794 citations John J.V. McMurray, Jan Östergren et al. profile →
  19. EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION
    1981 781 citations Karl Swedberg et al. profile →
  20. Predictors of mortality and morbidity in patients with chronic heart failure
    2005 757 citations Stuart Pocock, Marc A. Pfeffer et al. profile →
  21. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure
    2007 752 citations Stuart Pocock, John J.V. McMurray et al. profile →
  22. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
    2006 733 citations Marc A. Pfeffer, Karl Swedberg et al. Circulation profile →
  23. Heart failure with preserved left ventricular systolic function
    2004 705 citations Karl Swedberg, John J.V. McMurray et al. profile →
  24. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients
    2005 609 citations Scott D. Solomon, Hicham Skali et al. Circulation profile →
  25. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    2008 503 citations Mark C. Petrie, Jan Östergren et al. profile →
  26. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure
    2007 457 citations Scott D. Solomon, Joanna Dobson et al. Circulation profile →
  27. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
    2013 400 citations Karl Swedberg, James B. Young et al. profile →
  28. Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)
    2013 339 citations John J.V. McMurray, Milton Packer et al. European Journal of Heart Failure profile →
  29. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
    2015 302 citations Akshay S. Desai, John J.V. McMurray et al. profile →
  30. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
    2018 291 citations Pardeep S. Jhund, Martin Lefkowitz et al. profile →
  31. Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum
    2018 276 citations Pardeep S. Jhund, Giuseppe Rosano et al. European Journal of Heart Failure profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Karl Swedberg 53.2k 9.6k 8.7k 5.9k 4.1k 507 64.0k
Milton Packer 52.9k 1.0× 10.6k 1.1× 8.5k 1.0× 9.4k 1.6× 7.3k 1.8× 655 65.6k
Gerasimos Filippatos 30.8k 0.6× 7.9k 0.8× 7.5k 0.9× 6.3k 1.1× 5.0k 1.2× 625 43.8k
Dirk J. van Veldhuisen 43.8k 0.8× 5.6k 0.6× 7.7k 0.9× 7.9k 1.3× 5.7k 1.4× 857 60.8k
Javed Butler 29.1k 0.5× 8.1k 0.8× 6.2k 0.7× 6.4k 1.1× 4.5k 1.1× 825 42.1k
Aldo P. Maggioni 35.8k 0.7× 9.5k 1.0× 5.4k 0.6× 8.0k 1.4× 4.3k 1.0× 873 49.2k
Adriaan A. Voors 28.3k 0.5× 5.7k 0.6× 7.2k 0.8× 5.6k 0.9× 5.1k 1.3× 688 41.4k
Faı̈ez Zannad 38.6k 0.7× 19.2k 2.0× 11.6k 1.3× 10.2k 1.7× 7.7k 1.9× 958 57.7k
Clyde W. Yancy 48.4k 0.9× 3.6k 0.4× 5.6k 0.6× 7.4k 1.3× 2.9k 0.7× 603 60.3k
Giuseppe Mancia 46.3k 0.9× 11.8k 1.2× 4.2k 0.5× 10.8k 1.8× 2.8k 0.7× 1.3k 63.5k
Piotr Ponikowski 30.2k 0.6× 6.4k 0.7× 6.8k 0.8× 4.7k 0.8× 4.4k 1.1× 799 44.7k

Countries citing papers authored by Karl Swedberg

Since Specialization
Citations

This map shows the geographic impact of Karl Swedberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Swedberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Swedberg more than expected).

Fields of papers citing papers by Karl Swedberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Swedberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Swedberg. The network helps show where Karl Swedberg may publish in the future.

Co-authorship network of co-authors of Karl Swedberg

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Swedberg. A scholar is included among the top collaborators of Karl Swedberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Swedberg. Karl Swedberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gyllensten, Hanna, et al.. (2025). Person-Centred Care: State-of-the-Art and Future Perspectives. Current Heart Failure Reports. 22(1). 15–15.
2.
Moreno, Ana Cristina Perez, Nathaniel M. Hawkins, Alan Brunton, et al.. (2015). Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure. 17(2). 196–204. 13 indexed citations
3.
Cannon, Jane A., Timothy Collier, Li Shen, et al.. (2015). Clinical Outcomes According to QRS Duration and Morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 17(7). 707–716. 17 indexed citations
4.
Bello, Natalie A., Eldrin F. Lewis, Akshay S. Desai, et al.. (2015). Increased Risk of Stroke with Darbepoetin Alfa in Anaemic Heart Failure Patients with Diabetes and Chronic Kidney Disease. European Journal of Heart Failure. 17(11). 1201–1207. 34 indexed citations
5.
Komajda, Michel, Michael Böhm, Jeffrey Borer, et al.. (2014). Efficacy and Safety of Ivabradine in Patients with Chronic Systolic Heart Failure According to Blood Pressure Level in SHIFT. European Journal of Heart Failure. 16(7). 810–816. 53 indexed citations
6.
Voors, Adriaan A., Dirk J. van Veldhuisen, Michele Robertson, et al.. (2014). The Effect of Heart Rate Reduction with Ivabradine on Renal Function in Patients with Chronic Heart Failure: An Analysis from SHIFT. European Journal of Heart Failure. 16(4). 426–434. 43 indexed citations
7.
Rogers, Jennifer K., Stuart Pocock, John J.V. McMurray, et al.. (2014). Corrigendum to ‘Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved’ [ Eur J Heart Fail 2014;16:33–40]. European Journal of Heart Failure. 16(5). 592–592. 3 indexed citations
8.
Lainščak, Mitja, Luigi Tavazzi, Karl Swedberg, et al.. (2013). Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal. 42(Suppl 57). P1860–P1860. 1 indexed citations
9.
McMurray, John J.V., Inder S. Anand, Rafael Díaz, et al.. (2013). Baseline Characteristics of Patients in the Reduction of Events with Darbepoetin Alfa in Heart Failure Trial (RED-HF). European Journal of Heart Failure. 15(3). 334–341. 23 indexed citations
10.
Toma, Mustafa, Justin A. Ezekowitz, Jeffrey A. Bakal, et al.. (2013). The Relationship between Left Ventricular Ejection Fraction and Mortality in Patients with Acute Heart Failure: Insights from the ASCEND-HF Trial. European Journal of Heart Failure. 16(3). 334–341. 52 indexed citations
11.
Abrahamsson, Putte, Karl Swedberg, Jeffrey Borer, et al.. (2013). Risk Following Hospitalization in Stable Chronic Systolic Heart Failure. European Journal of Heart Failure. 15(8). 885–891. 35 indexed citations
12.
Dobre, Daniela, Jeffrey Borer, Keith A.A. Fox, et al.. (2013). Heart Rate: A Prognostic Factor and Therapeutic Target in Chronic Heart Failure. The distinct Roles of Drugs with Heart Rate-Lowering Properties. European Journal of Heart Failure. 16(1). 76–85. 65 indexed citations
13.
McMurray, John J.V., Milton Packer, Akshay S. Desai, et al.. (2013). Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF). European Journal of Heart Failure. 15(9). 1062–1073. 339 indexed citations breakdown →
14.
Spertus, John A., Alan B. Miller, S. Ward Casscells, et al.. (2013). Association of Low Body Temperature and Poor Outcomes in Patients Admitted with Worsening Heart Failure: A Substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trial. European Journal of Heart Failure. 15(12). 1382–1389. 17 indexed citations
15.
Tavazzi, Luigi, Karl Swedberg, Michel Komajda, et al.. (2013). Efficacy and Safety of Ivabradine in Chronic Heart Failure Across the Age Spectrum: Insights from the SHIFT Study. European Journal of Heart Failure. 15(11). 1296–1303. 60 indexed citations
16.
Preiss, David, Dirk J. van Veldhuisen, Naveed Sattar, et al.. (2012). Eplerenone and New-Onset Diabetes in Patients with Mild Heart Failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 14(8). 909–915. 55 indexed citations
17.
Sarma, Satyam, Robert J. Mentz, Mary Kwasny, et al.. (2012). Association Between Diabetes Mellitus and Post-Discharge Outcomes in Patients Hospitalized with Heart Failure: Findings from the EVEREST Trial. European Journal of Heart Failure. 15(2). 194–202. 137 indexed citations
18.
Mentz, Robert J., Bradley D. Allen, Mary Kwasny, et al.. (2012). Influence of Documented History of Coronary Artery Disease on Outcomes in Patients Admitted for Worsening Heart Failure with Reduced Ejection Fraction in the EVEREST Trial. European Journal of Heart Failure. 15(1). 61–68. 20 indexed citations
19.
Ambrosy, Andrew P., Muthiah Vaduganathan, Mark D. Huffman, et al.. (2012). Clinical Course and Predictive Value of Liver Function Tests in Patients Hospitalized for Worsening Heart Failure with Reduced Ejection Fraction: An Analysis of the EVEREST Trial. European Journal of Heart Failure. 14(3). 302–311. 146 indexed citations
20.
Solomon, Scott D., Joanna Dobson, Stuart Pocock, et al.. (2007). Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation. 116(13). 1482–1487. 457 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Milton Packer Breakdown of academic impact, for papers by Gerasimos Filippatos Breakdown of academic impact, for papers by Dirk J. van Veldhuisen Breakdown of academic impact, for papers by Javed Butler Breakdown of academic impact, for papers by Aldo P. Maggioni Breakdown of academic impact, for papers by Adriaan A. Voors Breakdown of academic impact, for papers by Faı̈ez Zannad Breakdown of academic impact, for papers by Clyde W. Yancy Breakdown of academic impact, for papers by Giuseppe Mancia Breakdown of academic impact, for papers by Piotr Ponikowski
Rankless by CCL
2026